Can you name the new components in apotex's ruxolitinib?

Do you mean the inactive ingredients (excipients) listed on Apotex’s ruxolitinib tablet label, or something else by “new components” (e.g., changes in formulation, new impurities, etc.)? Also, which regulatory region are you asking about (Canada Health Canada, US FDA, or another country)?

I don’t have real-time access to company-specific formulation data here, but I can help you find the exact information and interpret it. If you can tell me the jurisdiction, I can point you to the current label or product dossier. Alternatively, if you can share a link or the label text, I can extract and highlight the “inactive ingredients” and any notes about formulation changes.

Ways to locate the information yourself:
- US: Check Drugs@FDA or DailyMed for the Apotex ruxolitinib product label, then look under “Inactive ingredients” or “Description.” The label history may note any formulation changes.
- Canada: Search Health Canada’s Drug Product Database (DPD) or the product monograph for Apotex ruxolitinib to see the listed excipients.
- Compare with previous versions (if available) to identify any new components or changes.

If you want, tell me the region and I’ll guide you step-by-step or help interpret the label once you provide it.